METHOD OF MANAGING PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA IN A POLYCHEMOTHERAPY ACCORDING TO A FCR SCHEME AIMED AT PREVENTING CARDIOTOXICITY Russian patent published in 2020 - IPC A61B5/55 A61B8/06 G01N33/68 A61P9/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy, cardiology. hematology, and can be used for managing patients with chronic lymphatic leukemia in a polychemotherapy (PCT) according to a FCR scheme aimed at preventing cardiotoxicity. Perform echocardiography EchoCG, global longitudinal strain GLS evaluation and troponin level determination in biochemical blood analysis. Prior to prescribing polychemotherapy FCC according to a FCR scheme, patients underwent 3D-EchoCG and speckle tracking EchoCG with determination of GLS. High-sensitivity troponin T hscTnT is determined in biochemical blood analysis. If the ejection fraction EF of the left ventricular is below normal, then prior to PCT, cardioprotective therapy is prescribed with one preparation. After the PCT course similar examinations and patient's examination by the cardiologist is performed: if the cardiotoxicity is diagnosed, a second cardioprotective preparation is added to the treatment. Similar examinations are performed and the patient is examined by a cardiologist after each course of PCT. In the absence of cardiotoxicity after a PCT course, similar examinations and patient's examination by a cardiologist is performed once in 3 months. For the patients with the initial normal EF of the left ventricle, similar studies are conducted after 3 PCT courses: with reduction GLS>15 % of the initial value and an increase in the hscTnT level, one cardioprotective therapy is added to the therapy, similar examinations are performed and patient is examined by cardiologist once in 3 months. If GLS is relative reduced by ≤15 % after 3 courses of PCT, stress EchoCG with dobutamine is used to determine contractile reserve by GLS and if it is absent, 3D-EchoCG, speckle-tracking EchoCG with determination of GLS are performed once in 3 months and stress-EchoCG after PCT is completed. If observing the GLS reduction of ≤15 % after 3 PCT courses and the presence of the contractile GLS reserve in the stress-EchoCG patient, performing 3D-EchoCG, speckle-tracking EchoCG with GLS determination after PCT completion.

EFFECT: method enables administering patients with chronic lymphatic leukemia in the PCT according to the FCR scheme to prevent cardiotoxicity by a clear algorithm for interpreting results obtained during monitoring and monitoring the onset of cardiotoxicity in the patients in FCR chemotherapy.

1 cl, 5 ex